mardi 18 janvier 2022

La Fondation Bettencourt Schueller : Impulscience


 

La Fondation accompagne financièrement chaque projet sur une durée de 5 ans à hauteur de 2 millions d’euros, auxquels s’ajoutent la prise en charge des frais de gestion et la prime personnelle du chercheur.

 

Le premier appel à candidatures aura lieu en 2022.

 

Impulscience est ouvert aux chercheurs et chercheuses remplissant les conditions suivantes :

  • présenter un projet de recherche innovant dans les sciences de la vie ;
  • avoir répondu et avoir été sélectionné lors des appels à projets Starting, Consolidator ou Advanced de l’ERC de l’année précédente mais sans avoir obtenu le financement de l’ERC (classé A à l’issue de la seconde étape de l’évaluation ERC) ;
  • avoir moins de 50 ans au 1er janvier de l’année durant laquelle la candidature est évaluée par la Fondation Bettencourt Schueller et présenter sa candidature au minimum 5 ans après la date d’obtention du doctorat ;
  • travailler dans un laboratoire public en France au moment de la candidature ou au plus tard au moment du début du projet.

https://www.fondationbs.org/fr/sciences-de-la-vie/soutien-aux-chercheurs/impulscience

vendredi 21 janvier 2022

EIT Health Call for proposals: Innovation projects and Education programmes


The publication of this call is the beginning of a journey connecting those who understand and can identify the needs with those who have the solution to ultimately deliver value to patients and citizens, as well as to our healthcare systems by and large.

See complete version

lundi 31 janvier 2022

The Alzheimer's Drug Discovery Foundation (ADDF): Diagnostics Accelerator-Digital Biomarkers Program


 

The Diagnostics Accelerator is accepting applications on a rolling basis.

Exploratory awards: up to approximately $250,000

Proof-of-principle awards: up to $500,000

Validation awards: Award amounts will be based on stage and scope of research

 

Platforms : A variety of digital platforms such as portables, sensors, or software are encouraged. The proposed platform should have the potential to be easily deployed at scale. Passive approaches to data collection are encouraged.

Examples of digital approaches include, but are not limited to:

  • Wearables devices (e.g., smart watch)
  • Mobile/tablet apps
  • Smart home systems
  • Virtual and augmented reality platforms
  • Desktop/web apps

The following is out of scope for this RFP:

  • Diagnostic hardware for traditional digital imaging platforms (e.g. optical coherence tomography, neuroimaging)
  • Proposals focused on speech and language biomarkers

Note: The DxA is currently developing a speech and language biomarker consortium. Proposals outside this effort will not be considered at this time.

Symptom Domains : The RFP encourages digital biomarkers emerging from one or more of the symptom domains below. Proposed approaches will be evaluated based on the existing evidence around the biological link of the symptom domain to disease and how measuring the proposed symptom domain will improve current screening or monitoring methods in patients.

Symptom domains of interest include, but are not limited to:

  • Cognition (e.g. memory, processing speed, executive function, or geolocation)
  • Activities of Daily Living (instrumental basic activities or higher order activities)
  • Motor function (e.g. gait, body motion, or fine motor skills including tapping, swiping, and tracing on touchscreens)
  • Sensory Acuity (e.g. hearing, smell)
  • Affect (e.g. mood, facial expression)
  • Sleep Patterns and Characteristics
  • Oculomotor (e.g. eye movement)
  • Pain Assessment
  • Autonomic Nervous Function (e.g. heart rate, galvanic skin response)

Combinations of these or other symptom domains with a clear link to the disease are also encouraged.

 

Three stages of projects will be supported through this program:
  1. Exploratory awards will support pilot studies that aim to test the utility of an existing digital technology for the first time in an Alzheimer's disease or related dementia population. These projects should already have preliminary human data from another disease indication. For example, a pilot study would test a wearable gait monitoring device that has been tested in subjects with multiple sclerosis and is now being proposed to test in patients at risk for Alzheimer's. Only proposals with evidence demonstrating their technology or prototype can reliably capture, process, store, and transfer data from a clinical population will be considered. A limited number of awards will be considered in this category.
    Generally, projects at this stage will be awarded up to approximately $250,000 based on stage and scope of research. However, this is not a cap and higher funding levels will be considered if the proposed budget is well justified.

 

  1. Proof-of-principle awards will support projects that demonstrate feasibility and/or verify that a certain approach has potential for use in Alzheimer's disease or related dementias. Preliminary data from human subjects with the proposed indication is expected. For example, the disruption of sleep is an early change seen in Alzheimer's disease and a proof-of-principle project testing a device that is capable of detecting the stages and fragmentation of sleep would build on preliminary data acquired in the proposed patient population and proposed context of use, in addition to expanding the number of patients (e.g. ~100-200 subjects) tested with the sleep tracking device. Data must be provided demonstrating that the technology or prototype is capable of the reliable capture, processing, storage, and transfer of valid data to test in the clinical population.
    Generally, projects at this stage will be awarded up to approximately $500,000 based on stage and scope of research. However, this is not a cap and higher funding levels will be considered if the proposed budget is well justified.

 

  1. Validation awards will support projects that require testing at a larger scale and access to patients of varying demographic diversity to demonstrate clinical relevance. The technology must be verified and validated. Data quantifying the accuracy, precision, consistency, and uniformity of the technology must be provided. Applicants will be required to address scalability considerations, clinical integration plans, and anticipated regulatory considerations and commercialization. Data sharing policies and standards, intellectual property restrictions, and standard operating procedures should be well defined. Validation studies should prioritize comparisons using existing gold standard approaches to diagnose and monitor such as neuroimaging and/or CSF measurements, as well as clinical tests such as cognition, but this is dependent on the context of use. These studies will require a comprehensive experimental plan with larger sample size (e.g. 500-1000+ subjects based on power analyses). Award amounts will be based on the stage and scope of the research.

Projects that succeed in the exploratory or proof-of-principle stage may be eligible for follow-on funding in the form of a validation award.

https://www.alzdiscovery.org/research-and-grants/funding-opportunities/diagnostics-accelerator-digital-biomarkers-program

 

mardi 01 février 2022

The Focused Ultrasound Foundation


 

We fund high risk or clinically based investigator-initiated projects through the External Awards Program. We also fund projects in high-priority applications of FUS through the Brain Program, Cancer Immunotherapy Program, and Veterinary Program, including both invited and investigator-initiated projects.

Brain program: It is the ultimate goal of the Foundation's Brain Program to see focused ultrasound become a standard of care for the treatment of a range of neurological disorders, including movement disorders, brain tumors, epilepsy and stroke.

 

The External Awards Program provides funding for investigator-initiated clinical, preclinical, and early-stage research projects through a competitive peer-reviewed application process.

 

The program has two tracks:

* The Pre-Clinical Track is geared primarily towards preclinical studies and research projects that target a particular clinical indication or organ. It is meant to fund research that could lead the way to a new reimbursable clinical application for image-guided FUS within five to seven years.

 

*The High-Risk Track is intended for early-stage, high-risk, proof-of-concept research that, if successful, could have a profound impact on the field of focused ultrasound and that could change the way many conditions are treated.

 

**Additionally, the External Awards Program accepts abstracts for Clinical Trial funding requests. The abstract form for Clinical Trials is linked in the Materials section below. Funding for clinical trials is not limited to $100,000 and one year.

 

Funding: one-year awards totaling approximately $100,000

The Pre-Clinical Track typically does not fund large capital purchases, cannot fund overhead or institutional expenses, and will not fund the development of new focused ultrasound equipment

 

Application Process

Step 1: A one-page Research Abstract must be submitted at least two weeks prior to the program’s quarterly application deadlines (Feb. 1, May 1, Aug. 1, and Nov. 1).

Step 2: The Foundation will invite full Research Proposals from authors of approved Research Abstracts.

Funding decisions are returned to the applicant approximately three months after their application deadline.

 

https://fusfoundation.org/for-researchers/external-research-awards-program/apply-for-funding

https://fusfoundation.org/for-researchers/external-research-awards-program

 

Questions?

Please contact Matt Eames, PhD, Director of External Research, at meames@fusfoundation.org.

 

 

dimanche 13 février 2022

La Fondation pour la recherche sur les AVC : Appel à projets 2022


 

La Fondation pour la recherche sur les AVC finance des projets à hauteur de  25 000 à 50 000 €.

Date limite de candidature : 13 février.

http://www.fondation-recherche-avc.org/content/appel-%C3%A0-projets-2022-0

 

 

lundi 14 février 2022

The Leducq Foundation:  Call for International Networks of Excellence Program (INEP) 2021-2022


 

The Leducq Foundation has created the International Networks of Excellence in Cardiovascular and Neurovascular Research Program, (formerly the Transatlantic Networks of Excellence in Cardiovascular and Neurovascular Research Program) which promotes internationally collaborative basic, translational, and clinical research in cardiovascular and neurovascular disease. The principal aim of this program is to foster outstanding and innovative scientific research by bringing together international teams of researchers with complementary expertise and resources to work together on a common thematic problem. The proposals should aim to generate new knowledge with the potential to advance the diagnosis, prevention, and treatment of cardiovascular and/or neurovascular disease. Early career investigators play a vital role in these networks, which provide an excellent context for training and career development in cardiovascular and neurovascular research.

 

In the 2021-2022 application cycle, the Leducq Foundation will award four International Network of Excellence grants, each for an amount not to exceed U.S. $7,500,000 over five years.

 

Letter of Intent (LOI) Deadline: September 7, 2021

Notification of Application Status: November 1, 2021

Full Application Deadline: February 14, 2022

Scientific Advisory Committee Review: April 2022

Leducq Board of Directors Review: May 2022

Funding to Commence: January 1, 2023

 

With the International Network of Excellence (INE) Program, the Leducq Foundation looks to support original and outstanding research in the areas of the foundation’s mission, namely, cardiovascular and neurovascular disease. Applicants are encouraged to think innovatively and to propose bold new ideas.

 

Network activities should be oriented towards long-term goals, not at producing pre-defined results.

Leducq Foundation accepts applications in basic, translational, and clinical science, including collaborative “bench to bedside and back” programs.

 

Each network is built around an international research alliance involving two network coordinators, who must be located on different continents.

 

Interdisciplinary collaboration is particularly encouraged.

 

Size:

The size of the network may vary depending on the theme, on the type of research, and may not be determined fully at the outset. More important than the size of the network is the rationale for the inclusion of the members, and the case that is made for the collaborative benefit to be gained by their inclusion. At a minimum, a Leducq network should have three institutional members. As a general recommendation, the total number of institutions should not be greater than six, at which point the network becomes more difficult to manage. Applicants proposing to include more than six institutions in the network should discuss directly how the administrative and governance challenges associated with a larger network will be addressed. (For this purpose, INSERM units are considered separate institutions if they are at different universities and/or are administered by different INSERM délégations régionales.) All network applicants must demonstrate in the application how the composition of the network advances the scientific objectives of the research program.

 

International Network grants are not renewable. Members of concluding networks who wish to reapply with a team that consists of largely of the same participants, and with a theme similar to that of the existing network, are urged to present a new and original direction for research. All applications are considered on a de novo basis.

  • Network coordinators may not participate concurrently in any other Leducq network, in any capacity. Following the conclusion of the program of which they were the coordinators, they are ineligible to apply again to the International Networks of Excellence Program as a network coordinator, although they are eligible to participate as a member of another network. An exception is made for network members who, for whatever reason, have taken up the responsibility of network coordinator during the term of the network grant; they may apply to the foundation as the coordinator of a new network.
  • Network members may not participate in more than two Leducq International Networks concurrently. (This rule applies only to the 5-year term of the grant, and not to the no-cost extension period that networks may wish to pursue.)

 

Investigators are not permitted to submit more applications in an application cycle than the number in which they are allowed to participate if all applications were successful. Practically, this means that in any given year:

O Applicants for the role of coordinator cannot have their name on any other application submitted to the foundation.

O A member of a current Leducq network, which is expected to continue the following year, can be included in only one application to the foundation.

O An investigator not currently participating in a Leducq network can submit a maximum of either one application where his/her role will be that of coordinator, or two applications for that of member.

O An investigator who is a member of two Leducq networks can participate in a network application only when one of the networks of which he/she is a member comes to the end of its five-year term.

 

https://www.fondationleducq.org/international-networks-of-excellence-how-to-apply/how-to-apply/

https://www.fondationleducq.org/wp-content/uploads/2021/06/Program-Description-2021.pdf

 

 

jeudi 17 février 2022

NIH Funding Opportunities


NIH Funding Opportunities (Foreign Institutions are eligible to apply) / Financements NIH ouverts aux institutions non-US

Ensemble d'appels d'offres ouverts aux institutions non-US, on this page, a set of calls for proposals that are open to non-US institutions

jeudi 17 février 2022

Le plan France Relance et la préservation de l'emploi de R&D en santé.


 

Cette mesure permettra de conserver les capacités humaines de R&D des entreprises françaises en difficulté suite la crise sanitaire, en contribuant au financement de salaire de personnels, et en facilitant l’emploi de jeunes diplômés à travers des collaborations entre des laboratoires Inserm et les entreprises.

 

L’Inserm dispose ainsi d’un financement lui permettant de préserver ou de créer plus de 200 emplois R&D dans les entreprises ou ses laboratoires dans le domaine de la Santé. Inserm Transfert, la filiale de l'Institut dédiée à la valorisation, sera le point de contact des entreprises qui souhaitent bénéficier des crédits du plan France relance pour créer, relancer ou renforcer, des partenariats de recherche avec des équipes Inserm.

 

Un élément indispensable : un programme de recherche collaboratif

  • Un programme de recherche collaboratif encadré par un accord de collaboration est l’élément indispensable à la mise en œuvre du dispositif.

Préservation de l’emploi R&D grâce à 2 mesures :

  • Prise en charge d’une partie de la rémunération des personnels R&D du privé déjà en poste dans la société.
  • Recrutement de jeunes diplômés par l’Inserm.

https://www.inserm-transfert.fr/industriels/plan-france-relance/

https://www.inserm.fr/nous-connaitre/inserm-et-plan-france-relance/

jeudi 17 février 2022

The Alzheimer's Drug Discovery Foundation (ADDF):  Diagnostics Accelerator-Peripheral Biomarkers Program


 

The Diagnostics Accelerator is accepting applications on a rolling basis.

Exploratory awards: up to approximately $250,000

Proof-of-principle awards: up to $500,000

Validation awards: Award amounts will be based on stage and scope of research

 

Modalities: Blood and other peripheral markers, including saliva, urine, and ocular biomarkers are encouraged. The development of Cerebrospinal fluid (CSF) and neuroimaging biomarkers will not be considered for this program; however, we encourage the use of these modalities to validate proposed biomarkers.

Biomarker targets: Proposed approaches will be evaluated on biological plausibility linking the biomarker to disease pathophysiology. Examples of target areas of interest include, but are not limited to:

  • Vascular injury and blood-brain barrier integrity
  • Neuroinflammation
  • Neuroprotection and Neurodegeneration
  • Biomarkers of interest in fronto-temporal degeneration (FTD)
  • Protein misfolding
  • Synaptic integrity and/or activity
  • Mitochondria and metabolic function

Other novel approaches that are supported by compelling evidence that demonstrate a rational biological connection to the disease process are encouraged.

Sample sharing program: Clinical validation of a biomarker requires well characterized samples across multiple cohorts. The Diagnostics accelerator has partnered with Janssen/Shionogi, Eisai and Roche pharmaceuticals to make available samples from their clinical trials to our researchers.

The peripheral RFP is open to all biomarker categories that will advance drug development for Alzheimer's and related dementias. The expected context of use, which defines a biomarker's intended use clinically as a diagnostic or in drug development, should be described in the application. These categories, as defined by the FDA, include diagnostic, monitoring, predictive, prognostic, pharmacodynamic/response, safety, and susceptibility/risk biomarkers. Additionally, the applicant should articulate where in the path to commercialization the study falls and what is the proposed plan forward.

 

The following types of projects will be supported through this RFP:
  1. Exploratory awards will support pilot studies that aim to test the utility of an existing fluid biomarker approach for the first time in an Alzheimer's disease or related dementia population. These projects should already have preliminary human data from another disease indication. A limited number of awards will be considered in this category.
    Generally, projects at this stage will be awarded up to approximately $250,000 based on stage and scope of research. However, this is not a cap and higher funding levels will be considered if the proposed budget is well justified.
  2. Proof-of-principle awards will support exploratory analyses of biomarkers at a small scale (e.g., 50-100 human samples) that are supported by human data demonstrating that the candidate markers correspond with disease pathophysiology. Preliminary assay validation data for the proposed studies should be included.
    Generally, projects at this stage will be awarded up to $500,000 based on stage and scope of research. However, if there is a compelling reason to go above this level, please justify this in your full proposal if invited.
  3. Validation awards will support biomarkers that need to be tested at a larger scale (e.g., 500-1000 samples) and are supported by a significant body of human data demonstrating that the biomarker(s) correspond with disease pathophysiology. Applicants should be able to address how validation studies would move the biomarker towards the clinic and should define their strategies for regulatory approval and commercial scale-up. Assays should be well developed. Proposals should consider compatibility with existing sampling infrastructure, scalability, and intellectual property position, and standard operating procedures should be in place. Validation studies should compare peripheral analytes to quantitative measurements using PET and/or CSF, going beyond comparisons to cognition alone. Award amounts will be based on stage and scope of research.

Projects that succeed in the exploratory or proof-of-principle stage may be eligible for follow-on funding.

https://www.alzdiscovery.org/research-and-grants/funding-opportunities/diagnostics-accelerator-peripheral-biomarkers-program

jeudi 24 février 2022

Funding opportunities from International Foundations


Sur cette page découvrez les possibilités de financement de fondations internationales en fonction de vos thématiques.

 

Ci dessous une version exel

lundi 28 février 2022

Financial support to the organization of scientific events


 

 

More information : please download the document

lundi 28 février 2022

ARSEP: Working Visits


 

To facilitate exchanges between clinical centres and/or laboratories involved in MS. Travel may be within, to, or from France.

  • The training period can be up to 6 months.
  • Funding requests for up to 6.000 € to cover travel and accommodation are permitted.

Deadline: No deadline - throughout the year

https://www.arsep.org/fr/220-calls-for-proposals.html

https://www.arsep.org/library/media/other/Scientifique/Regulation-Working-visits-Travel-Grants-website.pdf

mardi 01 mars 2022

The France-Stanford Center for Interdisciplinary Studies


 

The France-Stanford Center for Interdisciplinary Studies, founded in partnership with the French Ministry of Foreign Affairs, bridges the disciplines of the Humanities, Social Sciences, Engineering, Business and Law, addressing issues of significance for France and the U.S. from a broad range of perspectives. It is part of Stanford Global Studies in the School of Humanities and Sciences.

 

Collaborative research projects

The France-Stanford Center for Interdisciplinary Studies invites proposals for collaborative research projects to be held during academic year 2022-23 (September 1, 2022 to August 31, 2023).

Priority will be given to projects with the potential to develop new collaborations involving junior researchers, and to those leading to collaborative work on interdisciplinary issues. Applications must be submitted jointly by researchers affiliated with a French institution and researchers in any Stanford department, as long as they are eligible to serve as principal investigators.

Deadline for applications: March 1, 2022

Budget: Projects will be funded up to $15,000 (USD).

Duration: One academic year (September 1 - August 31). Project extensions are available in some cases.

Expenses: The grant may be used for travel, lodging, and living costs, as well as research-related services. The grant may not be used for purchasing equipment, tuition fees, conference registration fees, salary payments nor publishing fees.

https://francestanford.stanford.edu/funding/collaborative-research-projects

https://francestanford.stanford.edu/sites/francestanford/files/media/file/collaborative_research_cfp_2022-23.pdf

francestanford@stanford.edu

 

Visiting Junior Scholar Fellowship

The France-Stanford Center Visiting Junior Scholar Fellowship is open to scholars who have completed a Ph.D. no more than three years from the date of applying for the fellowship and who hold a tenure-track/permanent position or a postdoctoral position. These may be Stanford-based scholars seeking a research visit at a French institution or scholars based in a French institution seeking a research visit at Stanford.

The France-Stanford Center for Interdisciplinary Studies invites proposals for junior scholar fellowship research projects to be held during academic year 2022-23 (September 1, 2022 through August 31, 2023).

Deadline for applications: March 1, 2022

Eligibility: Scholars affiliated with Stanford University or a French Institution and who have completed a Ph.D. no more than three years from the date of applying to the fellowship and postdoctoral students.

Budget: Visits will be funded up to $7,000 (USD).

Duration: Two to four months.

Expenses: The grant may be used for travel, lodging, and living costs. The grant may not be used for purchasing equipment, supplies or software, tuition fees, conference registration fees, salary payments nor publishing fees.

https://francestanford.stanford.edu/funding/visiting-junior-scholar-fellowship

https://francestanford.stanford.edu/sites/francestanford/files/media/file/Visiting%20Junior%20Scholar%20Fellowship%20CFP%20%282022-23%29_updated.pdf

francestanford@stanford.edu

mercredi 02 mars 2022

Bpifrance : Appel à Projets "Evaluation du bénéfice médical et / ou économique des dispositifs médicaux numériques ou à base d’intelligence artificielle"


 

L’objectif de cet appel à projets est de soutenir les projets d’évaluation visant à évaluer le bénéfice des dispositifs médicaux numériques ou à base d’intelligence artificielle. Les résultats des projets devront directement permettre de justifier l'utilisation en pratique du dispositif testé.

Par dispositif médical numérique on entendra tout dispositif médical (DM), dispositif médical implantable actif (DMIA) ou dispositif médical de diagnostic in vitro (DMDIV) dont la composante numérique représente la part prépondérante de l’actif, ou la part prépondérante de la proposition de valeur.

 

La date limite de dépôt des dossiers est fixée au 2 mars 2022 à 12 heures.

 

Le projet doit :

  • présenter une demande d’aide d‘un montant compris entre 100000 Euros et 2 500 000 Euros. Les travaux associés à la demande d’aide ne doivent pas avoir commencé avant le dépôt de la demande d’aide ;
  • Les projets dont le montant d’aide sollicitée est inférieur à 200 000 Euros doivent être mono-partenaires ; les établissements de santé doivent dans ce cas être intégrés dans la catégorie “sous-traitance” de l’annexe financière.
  • proposer une assiette éligible de travaux qui ne fait pas ou n’a pas fait l’objet de financements publics hors du cadre du présent appel à projets : par l’État, les collectivités territoriales, l’Union européenne ou leurs agences ;
  • se dérouler sur une durée comprise entre 12 et 48 mois à compter d'une date postérieure à la clôture de l'appel à projets
  • Le projet doit exclusivement porter sur l'évaluation médicale et/ou économique du dispositif, à l’exclusion du développement technologique algorithmique ou d'apprentissage sur de nouvelles données.

 

Les projets d’évaluation peuvent porter sur une technologie :

  • qui n’est pas encore sur le marché. Dans ce cas, le porteur du projet devra démontrer que ce développement technologique a été réalisé suivant un système de management de la qualité permettant d’obtenir sa mise sur le marché à l’horizon de la fin de l’étude. Ces projets incluront dans le dossier de candidature le rapport d’audit interne permettant d’attester de la mise en place du système de management de la qualité ; ou :
  • qui est déjà sur le marché et a déjà obtenu un marquage CE et/ou FDA. Ces projets incluront dans le dossier de candidature les documents attestant de l’obtention du marquage CE / FDA. Dans les deux cas, les documents acceptés sont précisés dans le cahier des charges.

 

Porteur(s) du projet :

  • Dans le cas d’un projet monopartenaire : être porté par un établissement unique responsable du développement du dispositif. Les coûts des établissements de santé partenaires de l’étude sont alors à intégrer dans la catégorie sous-traitance ;
  • Dans le cas d’un projet collaboratif : être porté par un consortium composé d’au moins un établissement de santé et de l’établissement en charge du développement du dispositif, dans la limite de 3 partenaires ;
  • Le porteur ou l’établissement chef de file doit être l’établissement responsable du développement technologique ;
  • Le porteur ou l’établissement chef de file doit démontrer la mise en œuvre effective d’un système de management de la qualité : marquage CE ou FDA ou rapport d’audit interne ;
  • Le porteur ou l’établissement chef de file doit être une personne morale enregistrée en France ;
  • Il n’y a pas de contraintes sur la nature des établissements : public / privé / associations / fondations ;

 

Type de dépenses :

  • Salaires et charges : Salaires chargés du personnel du projet (non environnés) appartenant aux catégories suivantes : chercheurs (post-doc inclus), ingénieurs, techniciens.
  • Frais connexes : Montant forfaitaire des dépenses de personnel (salaires chargés non environnés) et/ou d’équipements (amortissements), selon les cas. 4
  • Coûts de sous-traitance : Coûts de prestations utilisées exclusivement pour l'activité du projet, y compris évaluation. (cible : 60% max des coûts projet dans le cas général)
  • Contribution aux amortissements : Coûts d'amortissements comptables des instruments et du matériel de R&D au prorata de leur utilisation dans le projet. Exemple : pour un équipement amorti de façon linéaire sur une durée de 10 ans, et utilisé durant 2 ans pour le projet, le montant éligible à une aide sera égal à 2/10 du montant total de l’investissement dans cet équipement.
  • Coûts de refacturation interne : Sur la base de modalités de calcul détaillées et de la certification par un commissaire aux comptes ou expert-comptable. Pour des entreprises avec le même SIREN.
  • Frais de mission : Frais réels des déplacements liés à la réalisation du projet.
  • Autres coûts : Autres frais d'exploitation directement liés à l'activité du projet. (consommables non amortis dans les comptes)

 

https://www.bpifrance.fr/nos-appels-a-projets-concours/appel-a-projets-evaluation-du-benefice-medical-et-ou-economique-des-dispositifs-medicaux-numeriques-ou-a-base-dintelligence-artificielle

lundi 07 mars 2022

MQ: Fellows Award


 

up to £225,000, 3 years

Applications open 7th March 2022

https://www.mqmentalhealth.org/research-programmes/fellows-award/?utm_campaign=research-reoundup&utm_source=e-mail&utm_medium=MQ%20mental%20health%20research&utm_term=all&utm_content=rr140122-1stbutton&mc_uid=d119426064

 

mardi 08 mars 2022

ERA-NET NEURON Call 2022: Multinational and translational research projects on Cerebrovascular diseases including small vessels and brain barriers Dysfunction


 

Deadline for pre-proposals: March 8, 2022

https://www.neuron-eranet.eu/joint-calls/bio-medical/2022-cerebrovascular-diseases/

 

jeudi 24 mars 2022

INCa: PLBIO 2022


 

L'appel à projets libres « Biologie et Sciences du Cancer » est ouvert à l'ensemble des domaines de la recherche en biologie fondamentale et des disciplines scientifiques participant à la lutte contre le cancer afin de permettre l'acquisition de nouvelles connaissances sur les pathologies tumorales, de développer de nouveaux outils et d'ouvrir de nouvelles perspectives thérapeutiques.

La soumission de projets ayant des contributions disciplinaires autres que la biologie est fortement encouragée. La partie biologique doit être significativement développée et pertinente.

 

La durée des projets est de 36 ou 48 mois.

 

Des lettres d'intention : 2 novembre 2021 à 16h00,

Des projets finalisés : 24 mars 2022 à 16h00

 

Recommandations : Cet appel à projets est très compétitif, il est donc vivement conseillé aux porteurs de projets de respecter les objectifs de l'appel à projets et de présenter des projets répondant aux critères suivants :

  • Une pertinence scientifique vis-à-vis du cancer ;
  • Des projets originaux dans l'hypothèse et l'approche ;
  • Une méthodologie robuste, incluant des approches alternatives et des études mécanistiques ;
  • Des projets matures présentant une preuve de concept (données préliminaires).

 

La subvention L'Institut national du cancer pourra financer :

  • Des frais de personnel (le personnel permanent peut être imputé sur les dépenses éligibles du projet à l'exclusion des fonctionnaires
  • d'état, hospitaliers ou territoriaux). Le financement de post­ doctorants peut être demandé ; celui de doctorants n'est en revanche pas éligible;
  • Des frais de fonctionnement notamment :

-des consommables liés à la réalisation du projet (petit matériel, produit de laboratoire, tests) à l'exception des consommables de bureau qui relèvent des frais de gestion ;

-des frais de propriété intellectuelle de brevets ou licences induits par la réalisation du projet ;

-des frais liés à la publication des résultats financés y compris, par exemple, les surcoûts éventuellement appliqués pour la publication des articles en accès ouvert ;

-des frais de déplacement ou de missions des personnels permanents ou temporaires affectés au projet (congrès, colloque, monitoring d'ARC/TEC, etc) ;

-des frais d'organisation de réunions, séminaires en lien avec le projet et dans la limite de la durée du projet (location de salle et location de matériel) à l'exception des frais de réception qui relèvent des frais de gestion ;

-des prestations de services : le bénéficiaire de la subvention peut faire exécuter des prestations par des tiers extérieurs au projet ;

-des dépenses justifiées par une procédure de facturation interne : ces dépenses correspondent à des prestations ayant donné lieu à une tarification et traçables en comptabilité, réalisées par une entité (service, département, etc..) du bénéficiaire. Cette facturation interne doit être proportionnée à l'utilisation effective des prestations pour les besoins du projet ;

  • De l'équipement pour un montant inférieur à 150 K€ TTC. Ce seuil de 150K€ s'applique par achat unitaire d'équipement (et non pas sur le montant total des dépenses d'équipement). De plus, le montant total des dépenses d'équipement ne pourra être supérieur à 30 % du montant de la subvention allouée par l'Institut
  • Des frais de gestion : à hauteur de 8 % maximum du coût total des dépenses éligibles (personnel, fonctionnement, équipement) effectivement payées. Les frais de gestion ont un caractère forfaitaire et recouvrent :

-les frais d'administration générale en lien avec la gestion administrative et le suivi du projet (tels que notamment le temps administratif dédié aux conventions de reversement des fonds, suivi des financements des équipes participantes), l'achat de consommables de bureau, papeterie, etc. ;

-les frais de réception des réunions, colloques et séminaires (plateaux repas, cocktail) ;

https://projets.e-cancer.fr/

jeudi 31 mars 2022

La Fondation EDMUS & a Fondation ARSEP : Appel à projets contre la sclérose en plaques


 

100 000€

Date limite : 31 mars 2022

https://www.fondation-edmus.org/fr/la-recherche/appel-a-projets

 

jeudi 31 mars 2022

Fondation ARSEP: Appel à projets sur la Sclérose en plaque


 

  • Annual Call
  • Emergence-Network
  • Approche personnalisée, éthique, sociologique et économique de la SEP par la recherche

Deadline: March 31 2022

https://www.arsep.org/fr/220-calls-for-proposals.html

 

vendredi 01 avril 2022

JSMF Understanding Human Cognition program: JSMF Opportunity Awards


 

Deadline: April 1, 2022,

up to $250,000 over 2-4 years

https://www.jsmf.org/apply/opportunity/

mardi 28 juin 2022

EU Joint Programme – Neurodegenerative Disease Research: Understanding the mechanisms of non-pharmacological interventions.


 

Deadlines:

Pre-proposals: March 1, 2022

Full proposals: June 28, 2022

https://www.neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/understanding-the-mechanisms-of-non-pharmacological-interventions/